PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13133793::ACT044552

LCKLSL

Evidence text

Paper-level observation

Maximal HUVEC metabolic activity was observed under 24-h hypoxic induction, with subsequent dose-response analysis identifying 10 μM LCKLSL as the optimal concentration for significant anti-proliferative effects (Figure 4A and B).
textConfidence: medium

Assay observation

Activity
Toxicity
Subtype
Cytotoxic
Measure
cell_viability
Comparator
=
Raw observation
10 μM LCKLSL as the optimal concentration for significant anti-proliferative effects
Normalized measurement
=10
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
HUVEC
Assay method
Not reported by source
Sequence
LCKLSL
Standardization
ready simple

Source publication

Study on the Role of Short Peptide LCKLSL Targeting ANXA2 in Retinal Neovascularization.

In Vivo · 2026

DOI 10.21873/invivo.14291 PMC13133793
Parent mention

Related peptide identities

PEPDIA-PLP-001707

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.